Clinical Efficacy of Actovegin in Complex Treatment of Patients with Diabetes Mellitus Type 2 with Diabetic Polyneuropathy Against Arterial Hypertension
The aim of the study — to evaluate the clinical efficacy of Actovegin in complex treatment of patients with diabetes mellitus (DM) type 2 diabetic polyneuropathy (DPN) with arterial hypertension (AH). We observed 53 patients with DM type 2 with DPN against AH, who served as controls (n = 25) and study
(n = 28) group. Patients of study group in addition to the basic therapy received intravenous infusions of 400 mg of Actovegin for 10 days. It is found that the use of Actovegin in comprehensive treatment of DM type 2 with DPN against AH improves the clinical picture of the disease, which is associated with reduction in intensity of thirst, dry mouth, weakness, rapid fatigability, headache and dizziness, normalization of blood pressure. Actovegin has a positive effect on symptoms of DPN, resulting an increase in all kinds of sensitivity, decrease in degree of pain syndrome. Administration of Actovegin in the treatment of DM type 2 improves the glycemic profile, reduces the level of peripheral insulin resistance, and also has a beneficial potentiating action on the abnormal lipid metabolism.
Full Text:PDF (Українська)
Law D.W. The worldwide diabetes epidemic / D.W. Law, D. LeRoith // Curr. Opin. Endocrinol. Diabetes Obes. — 2012. — Vol. 19, № 2. — P. 93-96.
Кисляк О.А. Сахарный диабет 2 типа, артериальная гипертензия и риск сердечно-сосудистых осложнений / О.А. Кисляк, Т.О. Мышляева, Н.В. Малышева // Сахарный диабет. — 2008. — № 1(38). — С. 45-49.
Ndip A. Neuropathic diabetic foot ulcers — evidence-to-practice / A. Ndip, L. Ebah, A. Mbako // Int. J. Gen. Med. — 2012. — Vol. 5. — P. 129-134.
Won J.C. Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with Type 2 diabetes in Korea / J.C. Won, H.S. Kwon, C.H. Kim [et al.] // Diabet. Med. — 2012. — Vol. 29, № 9. — P. 290-296.
Dieckmann A. Treatment with Actovegin® improves sensory nerve function and pathology in streptozotocin-diabetic rats via mechanisms involving inhibition of PARP activation / A. Dieckmann, M. Kriebel, E. Andriambeloson [et al.] // Exp. Clin. Endocrinol. Diabetes. — 2012. — Vol. 120, № 3. — P. 132-138.
This work is licensed under a Creative Commons Attribution 4.0 International License.
© "Publishing House "Zaslavsky", 1997-2018